LONDON--(BUSINESS WIRE)--Technavio presents its latest pipeline analysis report on the anaplastic astrocytoma market. The report includes an in-depth analysis of the pipeline molecules under investigation within the defined data collection period to treat anaplastic astrocytoma.
This new report will offer an insight into several factors, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market during the forecast period.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Save more with Technavio. Buy 2 reports and get the third for FREE: View all Technavio’s current offers
Anaplastic astrocytoma- market overview and forecast
Anaplastic astrocytoma is an uncommon malignant brain tumor. Astrocytomas are the tumors, which are created by some star-molded brain cells that are called astrocytes. Astrocytes and similar cell-shaped tissues encompass and secure other nerve cells, which are found in the brain and the spinal cord. These cells are known as glial cells and the tissues they form are called glial tissues. Tumors that emerge from glial tissues, including astrocytomas are collectively called gliomas.
According to a senior analyst at Technavio for infectious and rare diseases, “The symptoms of anaplastic astrocytoma shift contingent on the area and the size of the tumor. The cause of this tumor is obscure. The side effects of anaplastic astrocytoma vary depending on the location and the size of the tumor. Most indications result from increased pressure within the brain. Anaplastic astrocytoma usually grows slowly, but after some time it may grow quickly.”
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Anaplastic astrocytoma market segmentation
This market research report segments the anaplastic astrocytoma market based on therapies employed (monotherapy and combination therapy), RoA (oral, IV, intra-arterially, oral+IV, and unspecified), types of molecules used (small molecule, biomolecule, monoclonal, and vaccine), targets for drugs under development (ornithine decarboxylase, thymidine kinase, caspase-3, EGFRvlll, immune suppressive myeloid cells, EGFR, mTOR and RCC, aurora A kinase, ErbB, LRP-1, pan-KIT and pan-PDGFRa, ERK-5, JAK-2 and FLT-3, and unspecified), and recruitment status (recruiting, completed, active not recruiting, not yet recruiting, and unspecified).
Monotherapy is the use of a single drug to treat a disorder or a disease. In the current pipeline, 47% of all the molecules that are being invested are monotherapy.
Small molecules are chemically manufactured active substances that can enter the cells easily because they have a lower molecular weight of less than 900 Da. Around 53% of the types of molecules used to belong to the small molecules category.
Save big with Technavio this May!
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at email@example.com.